Vertigo and motion sickness. Part II: pharmacologic treatment

Ear, Nose & Throat Journal, Jan, 2006 by Timothy P. Zajonc, Peter S. Roland

(10.) Johnson GD. Medical management of migraine-related dizziness and vertigo. Laryngoscope 1998;108:1-28.

(11.) Timmerman H. Pharmacotherapy of vertigo: Any news to be expected? Acta Otolaryngol Suppl 1994;513:28-32.

(12.) Wood CD, Cramer DB, Graybiel A. Antimotion sickness drug efficacy. Otolaryngol Head Neck Surg 1981;89:1041-4.

(13.) Muth ER, Jokerst M, Stern RM, Koch KL. Effects of dimenhydrinate on gastric tachyarrhythmia and symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995;66:1041-5.

(14.) Dahl E, Offer-Ohlsen D, Lillevold PE, Sardvik L. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clin Pharmacol Ther 1984;36:116-20.

(15.) Kohl RL, Calkins DS, Robinson RE. Control of nausea and autonomic dysfunction with terfenadine, a peripherally acting antihistamine. Aviat Space Environ Med 1991;62:392-6.

(16.) Turner JS Jr, Jackson RT. Astemizole: Its use in patients with chronic vertigo and ENG signs--a pilot study of a new drug. Laryngoscope 1983;93:898-902.

(17.) Jackson RT, Turner JS Jr. Astemizole. Its use in the treatment of patients with chronic vertigo. Arch Otolaryngol Head Neck Surg 1987;113:536-42.

(18.) Kohl RL, Homick JL, Cintron N, Calkins DS. Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man. Aviat Space Environ Med 1987;58:1171-4.

(19.) Wood CD, Stewart JJ, Wood MJ, Mims M. Effectiveness and duration of intramuscular antimotion sickness medications. J Clin Pharmacol 1992;32:1008-12.

(20.) Lackner JR, Graybiel A. Use of promethazine to hasten adaptation to provocative motion. J Clin Pharmacol 1994;34:644-8.

(21.) Wood CD, Manno JE, Manno BR, et al. Evaluation of antimotion sickness drug side effects on performance. Aviat Space Environ Med 1985;56:310-16.

(22.) Wood CD, Graybiel A. The antimotion sickness drugs. Otolaryngol Clin North Am 1973;6:301-13.

(23.) Pedigo NW Jr, Brizzee KR. Muscarinic cholinergic receptors in area postrema and brain stem areas regulating emesis. Brain Res Bull 1985;14:169-77.

(24.) van Marion WF, Bongaerts MC, Christiaanse JC, et al. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. Clin Pharmacol Ther 1985;38:301-5.

(25.) Parrott AC. Transdermal scopolamine: A review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med 1989;60:1-9.

(26.) Parrott AC. Transdermal scopolamine: Effects of single and repeated patches upon aspects of vision. Hum Psychopharmacol 1986;3: 27-41.

(27.) Osterholm RK, Camoriano JK. Transdermal scopolamine psychosis [letter]. JAMA 1982;247:3081.

(28.) Luetje CM, Wooten J. Clinical manifestations of transdermal scopolamine addiction. Ear Nose Throat J 1996;75:210-14.

(29.) Hamill MB, Suelflow JA, Smith JA, et al. Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle-closure glaucoma. Ann Ophthalmol 1983;15:1011-12.

(30.) Gordon CR, Shupak A, Doweck I, Spitzer O. Allergic contact dermatitis caused by transdermal hyoscine. BMJ 1989;298:1220-1.